Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence
- PMID: 33555616
- PMCID: PMC7869929
- DOI: 10.1111/cns.13375
Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence
Erratum in
-
Corrigendum.CNS Neurosci Ther. 2021 Oct;27(10):1254. doi: 10.1111/cns.13721. Epub 2021 Aug 19. CNS Neurosci Ther. 2021. PMID: 34411429 Free PMC article. No abstract available.
Abstract
Recent research on second-generation long-acting injectable antipsychotics (LAI SGAs) has proven its effectiveness in minimizing medication nonadherence problem and reducing relapses. Administered by medical professionals, making quick detection of nonadherence possible, long-acting injectable antipsychotics (LAIs) facilitate immediate intervention and recovery process, and thus are favored by psychiatrists. Despite a higher initial cost with LAIs, the subsequent schizophrenia-related health costs for hospitalizations and outpatients are greatly reduced. With reference to guidelines published by psychiatric associations around the globe, this article looks at scenarios in Hong Kong on the management of severe mentally ill patients with regard to the use of a host of psychosocial interventions as well as LAI SGAs as a preferable treatment. In particular, it examines the benefits of using LAI SGAs for Hong Kong patients who demonstrated high nonadherence treatment rates due to their social environment. It assesses the rationale behind the early usages of LAI SGAs, which help to provide better recovery outcomes for patients.
Keywords: Hong Kong; antipsychotic agents; paliperidone palmitate; patient compliance; schizophrenia.
© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754. J Manag Care Spec Pharm. 2015. PMID: 26308223 Free PMC article.
-
Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements.CNS Neurosci Ther. 2021 Mar;27 Suppl 1(Suppl 1):5-11. doi: 10.1111/cns.13374. CNS Neurosci Ther. 2021. PMID: 33555614 Free PMC article. Review.
-
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.CNS Drugs. 2021 Nov;35(11):1189-1205. doi: 10.1007/s40263-021-00861-6. Epub 2021 Oct 11. CNS Drugs. 2021. PMID: 34636025 Free PMC article. Review.
-
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x. Pharmacoeconomics. 2016. PMID: 26883132 Free PMC article.
-
Temporal trends of antipsychotic utilization patterns in 62,607 patients with schizophrenia-spectrum disorders in Hong Kong: An 11-year population-based study with joinpoint regression analysis.J Psychiatr Res. 2025 Mar;183:144-149. doi: 10.1016/j.jpsychires.2025.02.017. Epub 2025 Feb 13. J Psychiatr Res. 2025. PMID: 39961232
Cited by
-
Corrigendum.CNS Neurosci Ther. 2021 Oct;27(10):1254. doi: 10.1111/cns.13721. Epub 2021 Aug 19. CNS Neurosci Ther. 2021. PMID: 34411429 Free PMC article. No abstract available.
-
Effect of Group Cognitive Behavioral Therapy on Patients with Early-Onset Schizophrenia.Alpha Psychiatry. 2024 Jun 1;25(3):407-412. doi: 10.5152/alphapsychiatry.2024.241524. eCollection 2024 Jun. Alpha Psychiatry. 2024. PMID: 39148598 Free PMC article.
-
Predictors of admission to an assertive outreach service for psychosis in Lebanon.PLOS Glob Public Health. 2022 Dec 28;2(12):e0001428. doi: 10.1371/journal.pgph.0001428. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962861 Free PMC article.
-
A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.BMC Psychiatry. 2025 Jan 20;25(1):52. doi: 10.1186/s12888-025-06493-0. BMC Psychiatry. 2025. PMID: 39833706 Free PMC article.
-
Public mental health services in Southern China and related health outcomes among individuals living with severe mental illness.Glob Health Res Policy. 2024 Aug 29;9(1):31. doi: 10.1186/s41256-024-00363-0. Glob Health Res Policy. 2024. PMID: 39210438 Free PMC article.
References
-
- Hospital Authority . Hospital Authority Mental Health Service Plan for Adults 2010–2015. Hong Kong, China: Hospital Authority; 2009.
-
- Department of Health . Fourth National Mental Health Plan – An agenda for collaborative government action in mental health 2009‐2014. Canberra, Commonwealth of Australia: Department of Health; 2009.
-
- Mental Health Network . The NHS Confederation. Fact sheet: Key Facts and Trends In Mental Health. London, UK: Mental Health Network; 2009.
-
- Fleischhacker WW, Miyamoto S. Pharmacological treatment of schizophrenia: current issues and future perspectives. Clin Neuropsychopharmacol Ther. 2016;7:1‐8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical